Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 109 Endometrial Neoplasms 16 Neoplasm Metastasis 10 Polycystic Ovary Syndrome 9 Ovarian Neoplasms 7 Neoplasms 7 Advanced Breast Cancer 5 Triple Negative Breast Neoplasms 4 Prostatic Neoplasms 4 Fallopian Tube Neoplasms 4 Recurrence 3 Infertility 3 Carcinoma, Intraductal, Noninfiltrating 3 Breast Neoplasms, Male 3 Squamous Cell Carcinoma of Head and Neck 2 Progesterone Resistance 2 Neoplasms by Site 2 Hereditary Sensory and Autonomic Neuropathies 2 Head and Neck Neoplasms 2 HR+/HER2- Breast Cancer 2 Estrogen Receptor-positive Breast Cancer 2 Endometrial Hyperplasia 2 Cystadenocarcinoma, Serous 2 Carcinoma, Non-Small-Cell Lung 2 Breast Diseases 2 Breast Cancer Metastatic 2 Breast Cancer Female 2 Uterine Cervical Neoplasms 1 Unilateral Breast Neoplasms 1 Small Cell Lung Carcinoma 1

Interventions

ribociclib 1 Tretinoin 1 Letrozole 1 Goserelin 1 Drug Therapy 1 Chemotherapy, Adjuvant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2 Negative Breast Cancer × Letrozole × 1 year × Clear all

NCT06953882 2026-05-26

SELECT

Yale University

Phase 2 Recruiting

HER2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡